Teva U.S. sales plummet, Copaxone sets record

Generics giant Teva Pharmaceutical Industries ($TEVA) suffered another decline in U.S. sales, dampening third-quarter results. The Israeli company saw net income drop by 12.8% to $916 million, with U.S. revenues dropping by a whopping 48% to $845 million, compared with a period last year marked by several new product launches. Report